Lipolysis Inhibitors Modulate Tumor Growth

To study the role of lipolysis in vivo, mice were given two different lipolysis inhibitors: Acipimox or Atglistatin. Acipimox is a niacin derivate that suppresses cyclic adenosine monophosphate (cAMP), leading to a general inhibition of lipolysis [48 (link)]. Atglistatin is a selective and competitive inhibitor of ATGL, leaving other lipases unaffected [49 (link)]. Mice received either vehicle, Acipimox (0.5 g/L, Sigma-Aldrich, St. Louis, MO, USA) in drinking water or Atglistatin (0.1 μmol/g, Cayman Chemical Company, Ann Arbor, MI, USA) by oral gavage for 14 days after E0771 transplantation. In the Acipimox study, the drinking water was replaced two times per week and the water consumption of each cage was monitored every 24 h.